Measured by its ability to neutralize IL‑6-induced proliferation in the T1126.96.36.199 mouse plasmacytoma cell line. The Neutralization Dose (ND50) is typically 0.05-0.15 µg/mL in the presence of 2.5 ng/mL Recombinant Human IL‑6.
Please Note: Optimal dilutions should be determined by each laboratory for each application.
are available in the Technical Information section on our website.
IL‑6 in Human PBMCs.
IL‑6 was detected in immersion fixed human peripheral blood mononuclear cells (PBMCs) treated with LPS and monensin using Mouse Anti-Human IL‑6 Monoclonal Antibody (Catalog # MAB2061R) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Non-adherent Cells.
Detection of IL‑6 in Human PBMCs by Flow Cytometry.
Human peripheral blood mononuclear cells (PBMCs) treated with 100 μg/mL LPS for 24 hours were stained with Mouse Anti-Human IL‑6 Monoclonal Antibody (Catalog # MAB2061R, filled histogram) or isotype control antibody (Catalog # MAB004, open histogram), followed by Phycoerythrin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0102B). To facilitate intracellular staining, cells were fixed with Flow Cytometry Fixation Buffer (Catalog # FC004) and permeabilized with Flow Cytometry Permeabilization/Wash Buffer I (Catalog # FC005). View our protocol for Staining Intracellular Molecules.
Cell Proliferation Induced by IL-6 and Neutralization by Human IL-6 Antibody.
Recombinant Human IL-6 (Catalog # 206-IL) stimulates proliferation in the T1188.8.131.52 mouse plasmacytoma cell line in a dose-dependent manner (orange line), as measured by Resazurin (Catalog # AR002). Proliferation elicited by Recombinant Human IL-6 (2.5 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human IL-6 Monoclonal Antibody (Catalog # MAB2061R). The ND50 is typically 0.05-0.15 µg/mL.
Preparation and Storage
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C, as supplied.
1 month, 2 to 8 °C under sterile conditions after opening.
6 months, -20 to -70 °C under sterile conditions after opening.
Interleukin 6 (IL-6) is a pleiotropic alpha -helical cytokine that plays important roles in acute phase reactions, inflammation, hematopoiesis, bone metabolism, and cancer progression. IL-6 activity is essential for the transition from acute inflammation to either acquired immunity or chronic inflammatory disease. It is secreted by multiple cell types as a 22‑28 kDa phosphorylated and variably glycosylated molecule (1‑4). Mature human IL-6 is 183 amino acids (aa) in length and shares 41% aa sequence identity with mouse and rat IL-6 (5). Alternate splicing generates several isoforms with internal deletions, some of which exhibit antagonistic properties (6‑9). Human IL-6 is equally active on mouse and rat cells (10). IL-6 induces signaling through a cell surface heterodimeric receptor complex composed of a ligand binding subunit (IL-6 R) and a signal transducing subunit (gp130). IL-6 binds to IL-6 R, triggering IL-6 R association with gp130 and gp130 dimerization (11). gp130 is also a component of the receptors for CLC, CNTF, CT-1, IL-11, IL-27, LIF, and OSM (12). Soluble forms of IL-6 R are generated by both alternate splicing and proteolytic cleavage (3). In a mechanism known as trans‑signaling, complexes of soluble IL-6 and IL-6 R elicit responses from gp130-expressing cells that lack cell surface IL-6 R (3). Trans‑signaling enables a wider range of cell types to respond to IL-6, as the expression of gp130 is ubiquitous, while that of IL-6 R is predominantly restricted to hepatocytes, leukocytes, and lymphocytes (3). Soluble splice forms of gp130 block trans‑signaling from IL-6/IL-6 R but not from other cytokines that utilize gp130 as a coreceptor (4, 13).
Van Snick, J. (1990) Annu. Rev. Immunol. 8:253.
Hodge, D.R. et al. (2005) Eur. J. Cancer 41:2502.
Jones, S.A. (2005) J. Immunol. 175:3468.
Rose-John, S. et al. (2006) J. Leukoc. Biol. 80:227.
Hirano, T. et al. (1986) Nature 324:73.
Alberti, L. et al. (2005) Cancer Res. 65:2.
Kestler, D.P. et al. (1995) Blood 86:4559.
Kestler, D.P. et al. (1999) Am. J. Hematol. 61:169.
Bihl, M.P. et al. (2002) Am. J. Respir. Cell Mol. Biol. 27:48.
Chiu, C.P. et al. (1988) Proc. Natl. Acad. Sci. USA 85:7099.
Murakami, M. et al. (1993) Science 260:1808.
Muller-Newen, G. (2003) Sci. STKE 2003:PE40.
Mitsuyama, K. et al. (2006) Clin. Exp. Immunol. 143:125.
Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.